The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through

Raffaella Soldi1, Tithi Ghosh Halder1, Samuel Sampson1

  • 1Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), Phoenix, Arizona (R.S., T.G.H., S.S., A.W., T.T., R.R.d.V., K.D., M.R.K., S.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah (H.V.); MD Anderson Cancer Center, University of Texas, Department of Leukemia, Division of Cancer Medicine, Houston, Texas (K.N.B.); Iterion Therapeutics, Inc., Houston, Texas (S.K.H.); College of Medicine, Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska (S.K.B.); City of Hope Comprehensive Cancer Center, Duarte, California (R.S.).

Insights

The Wnt signaling inhibitor BC-2059 targets the transducin beta-like 1 (TBL1)/beta-catenin complex. This selective disruption offers a potential therapeutic strategy for various cancers with deregulated Wnt pathways.

Area of Science:

  • Molecular Biology
  • Cancer Therapeutics
  • Signal Transduction

Background:

  • Aberrant Wnt signaling drives cancer development, making beta-catenin a key therapeutic target.
  • BC-2059 is a novel small-molecule inhibitor that induces apoptosis by disrupting the beta-catenin/transducin beta-like 1 (TBL1) complex.
  • The precise mechanism of BC-2059 action remained previously uncharacterized.

Purpose of the Study:

  • To elucidate the mechanism of action of the Wnt pathway inhibitor BC-2059.
  • To characterize the interaction between BC-2059, TBL1, and beta-catenin.
  • To determine the selectivity of BC-2059's inhibitory effects.

Main Methods:

  • Biochemical assays to assess protein complex interactions.
  • Site-directed mutagenesis to identify key amino acids in TBL1.
  • Computational modeling to predict drug-target interactions.
  • Assays to evaluate disruption of TBL1 interactions with other protein complexes.

Main Results:

  • BC-2059 directly binds to TBL1 with high affinity within the beta-catenin complex.
  • Two specific amino acids in a TBL1 hydrophobic pocket are crucial for beta-catenin binding.
  • Computational modeling indicated BC-2059 targets this same hydrophobic pocket on TBL1.
  • BC-2059 selectively disrupts the TBL1/beta-catenin interaction without affecting TBL1 interactions with NCoR/SMRT or NF-kappaB complexes.

Conclusions:

  • BC-2059 selectively targets and disrupts the TBL1/beta-catenin protein complex.
  • This targeted mechanism suggests BC-2059 as a promising therapeutic agent for cancers dependent on Wnt signaling.
  • The findings provide a mechanistic basis for BC-2059's efficacy in Wnt-driven tumors.

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.4K
Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
2.6K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.2K